Patent ID: 11951182
Assignee: MOMOTARO-GENE INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method for treating thoracic cancer which is resistant to anti-PD-1 or anti-PD-L1 antibody immunotherapy, comprising administering to a subject with thoracic cancer a combination consisting of an Ad-REIC/Dkk-3, a check point inhibitor, and a carrier, wherein the Ad-REIC/Dkk-3 is an adenovirus vector comprising:
(i) a CMV promoter;
(ii) the following REIC/Dkk-3 DNA:
(a) DNA comprising the nucleotide sequence shown in SEQ ID NO: 1, or
(b) DNA having at least 90% sequence identity with the nucleotide sequence shown in SEQ ID NO:1,

(iii) a polyA sequence; and
(iv) enhancers prepared by linking an human Telomerase Reverse Transcriptase (hTERT) enhancer, an SV40 enhancer, and a CMV enhancer, wherein the hTERT enhancer is 5′ of the SV40 enhancer, and the SV40 enhancer is 5′ of the CMV enhancer,
wherein the thoracic cancer is a mesothelioma or an EGFR-mutant lung cancer.